Reduced HFSR incidence observed in a randomized phase II study in advanced breast cancer patients treated with sorafenib and paclitaxel by initial ramp-up dose escalation (PASO). 1. Juni 2011 Overkamp, F., Steffens, C., Abenhardt, W., Lerchenmüller, C., Nusch, A., Göhler, T., Groschek, M., Hegewisch-Becker, S., Marschner, N., Rösel, S., Salat, C., Decker, T., 2011. J Cancer Res Clin Oncol 138(Suppl.1)(0026), 62. doi:10.1007/s00432-011-1144-4 Abstract Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. van de Velde, C.J.., Rea, D., Seynaeve, C., Putter, H., Hasenburg, A., Vannetzel, J.M., Paridaens, R., Markopoulos, C., Hozumi, Y., Hille, E., others, 2011. Lancet… Weiterlesen Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study. Bartlett, J.M.S., Bloom, K.J., Piper, T., Lawton, T.J., van de Velde, C.J.H., Ross, D.T., Ring, B.Z., Seitz, R.S., Beck, R.A., Hasenburg, A., Kieback, D., Putter,… Weiterlesen